Next Post

PolyPid licenses surgical infection prevention drug to Advanz

&#13 Israeli drug enhancement enterprise PolyPid (Nasdaq: PYPD) today introduced that it has entered into an exclusive licensing agreement in Europe with United kingdom-based mostly specialty and hospital pharmaceutical business Advanz Pharma (formerly Concordia Health care Corp.) for its lead drug prospect, D-PLEX100 for the prevention of surgical web-site bacterial […]